Esperion Therapeutics | ESPR - Stock


Esperion Therapeutics reported $108.54M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
AbbVie USD 4.94B 22M Sep/2025
Alnylam Pharmaceuticals USD 75.38M 3.7M Sep/2025
Amarin USD 184.7M 13.46M Sep/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.38B 42M Sep/2025
Cipla INR 61.6B 5.18B Sep/2025
CSL USD 6.47B 327M Jun/2025
Cytokinetics USD 0 0 Dec/2023
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Eli Lilly USD 12.18B 1.17B Sep/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Geron USD 95.42M 26.3M Sep/2025
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 185.8M 4.29M Sep/2025
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Merck USD 6.44B 157M Sep/2025
Moderna USD 332M 92M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 11.47B 201M Sep/2025
PTC Therapeutics USD 52.69M 18.63M Sep/2025
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1.08B 83.13M Sep/2025
United Therapeutics USD 176.5M 7.3M Sep/2025
Vanda Pharmaceuticals USD 2.04M 127K Sep/2025